We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
Read MoreHide Full Article
Exact Sciences Corp. (EXAS - Free Report) announced that the FDA has approved a label expansion of its noninvasive colorectal cancer screening test, Cologuard.
The test can now be used in eligible average-risk individuals aged 45 years or older, expanding on its previous indication for 50 years or older.
As a result of the broader label, approximately 19-million average-risk people in the United States from the age group of 45-49 years can now access a new, sensitive, at-home, stool-based screening test.
Cologuard is a stool DNA-based colorectal cancer screening test for average-risk individuals. The test uses a biomarker panel, which analyzes a person's stool sample for 10 DNA markers, as well as blood in the stool.
We note that the FDA approved Cologuard for the first time in August 2014. Colorectal cancer is the second deadliest cancer in the United States and an early screening will go a long way in better management of the disease.
Given the widespread prevalence of colorectal cancer among Americans under 50 years, the expanded label bodes well for molecular diagnostics company, Exact Sciences. Notably, in May 2018, the American Cancer Society (ACS) updated its colorectal cancer screening guidelines to include people between 45 years and 49 years, while the prior ACS recommendation called for screening to begin at age 50.
The news of the approval boosted the company’s stock price, which eventually retraced by the end of the day.
In July, Exact Sciences announced that it will acquire Genomic Health, Inc. for $2.8 billion, thereby creating a leading global cancer diagnostics company. The combined company will offer two of the strongest and fastest-growing brands in cancer diagnostics — Cologuard and Oncotype DX.
We remind investors that Exact Sciences also has a promotion agreement with Pfizer, Inc. (PFE - Free Report) , whereby the latter will promote Cologuard and provide certain sales, marketing, analytical and other commercial operations support services.
Meanwhile, Guardant Health, Inc. (GH - Free Report) is evaluating LUNAR RUO assay to identify early-stage colorectal cancer patients with post-operative molecular residual disease, who may benefit from adjuvant therapy.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
Exact Sciences Corp. (EXAS - Free Report) announced that the FDA has approved a label expansion of its noninvasive colorectal cancer screening test, Cologuard.
The test can now be used in eligible average-risk individuals aged 45 years or older, expanding on its previous indication for 50 years or older.
As a result of the broader label, approximately 19-million average-risk people in the United States from the age group of 45-49 years can now access a new, sensitive, at-home, stool-based screening test.
Cologuard is a stool DNA-based colorectal cancer screening test for average-risk individuals. The test uses a biomarker panel, which analyzes a person's stool sample for 10 DNA markers, as well as blood in the stool.
We note that the FDA approved Cologuard for the first time in August 2014. Colorectal cancer is the second deadliest cancer in the United States and an early screening will go a long way in better management of the disease.
Given the widespread prevalence of colorectal cancer among Americans under 50 years, the expanded label bodes well for molecular diagnostics company, Exact Sciences. Notably, in May 2018, the American Cancer Society (ACS) updated its colorectal cancer screening guidelines to include people between 45 years and 49 years, while the prior ACS recommendation called for screening to begin at age 50.
The news of the approval boosted the company’s stock price, which eventually retraced by the end of the day.
Exact Sciences Corporation Price
Exact Sciences Corporation price | Exact Sciences Corporation Quote
In July, Exact Sciences announced that it will acquire Genomic Health, Inc. for $2.8 billion, thereby creating a leading global cancer diagnostics company. The combined company will offer two of the strongest and fastest-growing brands in cancer diagnostics — Cologuard and Oncotype DX.
We remind investors that Exact Sciences also has a promotion agreement with Pfizer, Inc. (PFE - Free Report) , whereby the latter will promote Cologuard and provide certain sales, marketing, analytical and other commercial operations support services.
Meanwhile, Guardant Health, Inc. (GH - Free Report) is evaluating LUNAR RUO assay to identify early-stage colorectal cancer patients with post-operative molecular residual disease, who may benefit from adjuvant therapy.
Exact Sciences currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>